Heart Failure — United States (Pregnant Women population)
In women with a history of HF or cardiomyopathy
Patient-centered counseling regarding contraception and risks of cardiovascular deterioration during pregnancy should be provided.
In women with HF or cardiomyopathy who are pregnant or planning pregnancy
ACEi, ARB, ARNi, MRA, SGLT2i, ivabradine, and vericiguat should NOT be administered because of risks of fetal harm.
In women with acute HF caused by peripartum cardiomyopathy (PPCM) and LVEF <30%
Anticoagulation may be reasonable until 6 to 8 weeks postpartum.
Related Clinical Tools
